Machine Learning-Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention

被引:0
|
作者
Afshar, Majid [1 ]
Linck, Emma J. Graham [1 ]
Spicer, Alexandra B. [1 ]
Rotrosen, John [2 ]
Salisbury-Afshar, Elizabeth M. [1 ]
Sinha, Pratik [3 ]
Semler, Matthew W. [4 ]
Churpek, Matthew M. [1 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA
[2] NYU, Grossman Sch Med, New York, NY USA
[3] Washington Univ, Sch Med, St Louis, MO USA
[4] Vanderbilt Univ, Med Ctr, Nashville, TN USA
关键词
opioid use disorder; opioid treatment; heterogeneity of treatment effect; buprenorphine; naltrexone; EXTENDED-RELEASE NALTREXONE; RATING-SCALES; METHADONE; XBOT;
D O I
10.1097/ADM.0000000000001313
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Objective: A trial comparing extended-release naltrexone and sublingual buprenorphine-naloxone demonstrated higher relapse rates in individuals randomized to extended-release naltrexone. The effectiveness of treatment might vary based on patient characteristics. We hypothesized that causal machine learning would identify individualized treatment effects for each medication. Methods: This is a secondary analysis of a multicenter randomized trial that compared the effectiveness of extended-release naltrexone versus buprenorphine-naloxone for preventing relapse of opioid misuse. Three machine learning models were derived using all trial participants with 50% randomly selected for training (n = 285) and the remaining 50% for validation. Individualized treatment effect was measured by the Qini value and c-for-benefit, with the absence of relapse denoting treatment success. Patients were grouped into quartiles by predicted individualized treatment effect to examine differences in characteristics and the observed treatment effects. Results: The best-performing model had a Qini value of 4.45 (95% confidence interval, 1.02-7.83) and a c-for-benefit of 0.63 (95% confidence interval, 0.53-0.68). The quartile most likely to benefit from buprenorphine-naloxone had a 35% absolute benefit from this treatment, and at study entry, they had a high median opioid withdrawal score (P < 0.001), used cocaine on more days over the prior 30 days than other quartiles (P < 0.001), and had highest proportions with alcohol and cocaine use disorder (P <= 0.02). Quartile 4 individuals were predicted to be most likely to benefit from extended-release naltrexone, with the greatest proportion having heroin drug preference (P = 0.02) and all experiencing homelessness (P < 0.001). Conclusions: Causal machine learning identified differing individualized treatment effects between medications based on characteristics associated with preventing relapse.
引用
收藏
页码:511 / 519
页数:9
相关论文
共 50 条
  • [31] Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone and Injection Naltrexone
    Na, Peter J.
    Scodes, Jennifer
    Fishman, Marc
    Rotrosen, John
    Nunes, Edward V., Jr.
    JOURNAL OF CLINICAL PSYCHIATRY, 2022, 83 (03)
  • [32] Machine Learning Methods to Estimate Individualized Treatment Effects for Use in Health Technology Assessment
    Zhang, Yingying
    Kreif, Noemi
    Gc., Vijay S.
    Manca, Andrea
    MEDICAL DECISION MAKING, 2024, 44 (07) : 756 - 769
  • [33] Clinical Experience with Injectable Naltrexone Treatment in Sixteen Patients with Alcohol and Opioid Use Disorder: Retrospective Case Analysis
    Barnett, Brian
    Tebaldi, Christine
    McHugh, Kathryn
    Weiss, Roger
    Bogunovic, Olivera
    AMERICAN JOURNAL ON ADDICTIONS, 2017, 26 (03): : 291 - 292
  • [34] Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
    Schmith, Virginia D.
    Curd, Laura
    Lohmer, Lauren R. L.
    Laffont, Celine M.
    Andorn, Anne
    Young, Malcolm A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 106 (03) : 576 - 584
  • [35] Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment
    Mokri, Azarakhsh
    Chawarski, Marek C.
    Taherinakhost, Hamidreza
    Schottenfeld, Richard S.
    ADDICTION, 2016, 111 (05) : 874 - 882
  • [36] Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial
    Roache, John D.
    Pavlicova, Martina
    Campbell, Aimee
    Choo, Tse-Hwei
    Peavy, Michelle
    Kermack, Andrea S.
    Nunes, Edward V., Jr.
    Rotrosen, John
    ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2021, 45 (12): : 2569 - 2578
  • [37] Co-occurring Depression in Patients With Opioid Use Disorder: Prevalence and Response During Treatment With Buprenorphine-Naloxone or Extended- Release Naltrexone
    Na, Peter
    Scodes, Jennifer
    Pavlicova, Martina
    Fishman, Marc
    Rotrosen, John
    Nunes, Edward
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 253 - 253
  • [38] Association of Bupropion, Naltrexone, and Opioid Agonist Treatment with Stimulant-Related Events in Opioid Use Disorder: A Case-Crossover Analysis
    Xu, Kevin
    Mintz, Carrie
    Presnall, Ned
    Bierut, Laura
    Grucza, Richard
    AMERICAN JOURNAL ON ADDICTIONS, 2022, 31 (04): : 364 - 365
  • [39] Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis
    Salwan, Aaron
    Hagemeier, Nicholas E.
    Tudiver, Fred
    Dowling-McClay, Karilynn
    Foster, Kelly N.
    Arnold, Jessie
    Alamian, Arsham
    Pack, Robert P.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2020, 60 (06) : E173 - E178
  • [40] Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder
    Zullig, Keith J.
    Lander, Laura R.
    Sloan, Samantha
    Brumage, Michael R.
    Hobbs, Gerry R.
    Faulkenberry, Laurel
    MINDFULNESS, 2018, 9 (02) : 423 - 429